News
MNPR
72.68
+1.32%
0.95
Cantor upgrades Monopar Therapeutics on recent pullback, added clarity
TipRanks · 6h ago
Monopar Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
TipRanks · 6h ago
Monopar Therapeutics GAAP EPS of -$0.72 in-line
Seeking Alpha · 10h ago
*Monopar Therapeutics: Runway To Support Operations Through at Least March 2028 >MNPR
Dow Jones · 11h ago
*Monopar Therapeutics 3Q Loss $6.2M >MNPR
Dow Jones · 11h ago
Weekly Report: what happened at MNPR last week (1102-1106)?
Weekly Report · 3d ago
Weekly Report: what happened at MNPR last week (1026-1030)?
Weekly Report · 11/02 10:21
Weekly Report: what happened at MNPR last week (1019-1023)?
Weekly Report · 10/26 10:21
Weekly Report: what happened at MNPR last week (1012-1016)?
Weekly Report · 10/19 10:21
Weekly Report: what happened at MNPR last week (1005-1009)?
Weekly Report · 10/12 10:26
Weekly Report: what happened at MNPR last week (0928-1002)?
Weekly Report · 10/05 10:26
Piper Sandler Sticks to Their Buy Rating for Monopar Therapeutics Inc (MNPR)
TipRanks · 09/28 12:07
Weekly Report: what happened at MNPR last week (0921-0925)?
Weekly Report · 09/28 10:21
H.C. Wainwright Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR)
TipRanks · 09/22 09:45
Weekly Report: what happened at MNPR last week (0914-0918)?
Weekly Report · 09/21 10:21
Weekly Report: what happened at MNPR last week (0907-0911)?
Weekly Report · 09/14 10:26
Monopar Therapeutics Is Maintained at Overweight by Barclays
Dow Jones · 09/11 13:58
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145
Benzinga · 09/11 13:48
Monopar Therapeutics price target raised to $145 from $128 at Barclays
TipRanks · 09/11 09:30
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Monopar Therapeutics Inc (MNPR)
TipRanks · 09/11 09:20
More
Webull provides a variety of real-time MNPR stock news. You can receive the latest news about Monopar Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About MNPR
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.